HBM7020 in Healthy Adults and Adults With Seropositive Autoimmune Disease

Phase 1, open-label trial of HBM7020 in systemic lupus erythematosus (SLE), systemic sclerosis (SSc), Sjögren's syndrome and 1 more (2 arms), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoints: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Study Discontinuations Due to Adverse Events, Number of Participants With Signs Characteristic of Cytokine Release Syndrome (CRS), Immune Related Reaction (IRR), Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), Including… and 7 more. Started Sep 2026; status: recruiting.